Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.
Stemp G, Ashmeade T, Branch CL, Hadley MS, Hunter AJ, Johnson CN, Nash DJ, Thewlis KM, Vong AK, Austin NE, Jeffrey P, Avenell KY, Boyfield I, Hagan JJ, Middlemiss DN, Reavill C, Riley GJ, Routledge C, Wood M. Stemp G, et al. Among authors: reavill c. J Med Chem. 2000 May 4;43(9):1878-85. doi: 10.1021/jm000090i. J Med Chem. 2000. PMID: 10794704
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
Macdonald GJ, Branch CL, Hadley MS, Johnson CN, Nash DJ, Smith AB, Stemp G, Thewlis KM, Vong AK, Austin NE, Jeffrey P, Winborn KY, Boyfield I, Hagan JJ, Middlemiss DN, Reavill C, Riley GJ, Watson JM, Wood M, Parker SG, Ashby CR Jr. Macdonald GJ, et al. Among authors: reavill c. J Med Chem. 2003 Nov 6;46(23):4952-64. doi: 10.1021/jm030817d. J Med Chem. 2003. PMID: 14584946
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ. Reavill C, et al. J Pharmacol Exp Ther. 2000 Sep;294(3):1154-65. J Pharmacol Exp Ther. 2000. PMID: 10945872
Studies towards the identification of a new generation of atypical antipsychotic agents.
Garzya V, Forbes IT, Gribble AD, Hadley MS, Lightfoot AP, Payne AH, Smith AB, Douglas SE, Cooper DG, Stansfield IG, Meeson M, Dodds EE, Jones DN, Wood M, Reavill C, Scorer CA, Worby A, Riley G, Eddershaw P, Ioannou C, Donati D, Hagan JJ, Ratti EA. Garzya V, et al. Among authors: reavill c. Bioorg Med Chem Lett. 2007 Jan 15;17(2):400-5. doi: 10.1016/j.bmcl.2006.10.036. Epub 2006 Oct 19. Bioorg Med Chem Lett. 2007. PMID: 17084080
The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure.
Holmes IP, Blunt RJ, Lorthioir OE, Blowers SM, Gribble A, Payne AH, Stansfield IG, Wood M, Woollard PM, Reavill C, Howes CM, Micheli F, Di Fabio R, Donati D, Terreni S, Hamprecht D, Arista L, Worby A, Watson SP. Holmes IP, et al. Among authors: reavill c. Bioorg Med Chem Lett. 2010 Mar 15;20(6):2013-6. doi: 10.1016/j.bmcl.2010.01.090. Epub 2010 Jan 25. Bioorg Med Chem Lett. 2010. PMID: 20153647
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety.
Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, Lightowler S, Blackburn TP, Thomas D, Gager TL, Riley G, Holland V, Bromidge SM, Forbes IT, Middlemiss DN. Wood MD, et al. Among authors: reavill c. Neuropharmacology. 2001 Aug;41(2):186-99. doi: 10.1016/s0028-3908(01)00054-5. Neuropharmacology. 2001. PMID: 11489455
82 results